http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-012876-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37555e87c88017b74fba94c8b8abbb42 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 1998-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2000-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-012876-A1 |
| titleOfInvention | USE OF LOW MOLECULAR WEIGHT HEPARINES FOR THE PREPARATION OF MEDICINES FOR THE PREVENTION AND TREATMENT OF TRAUMA OF THE CENTRAL NERVOUS SYSTEM |
| abstract | Use of low molecular weight heparins for the preparation of medicines for the prevention and treatment of trauma to the central nervous system and, mainly, to spinal, cranial or cranio-spinal trauma. Standard heparin is a 12,000-15,000 dalton average molecular weight sulphated polysaccharide isolated from the intestinal mucosa of cattle, lambs and pigs. Heparin is used clinically for the prevention and treatment of thromboembolic disorders but sometimes causes bleeding. For a decade, heparin has been progressively replaced by low molecular weight heparins, which no longer have the drawback of bleeding, or only do so to a lesser degree, and which no longer need more than one injection per day , instead of 2 to 3 injections per day in the case of standard heparin. Injuries to the central nervous system affect trauma to the brain (brain trauma) and trauma to the spinal cord (spinal trauma). The consequences of these traumas are neurological disorders such as epilepsy, altered consciousness, motor problems, amnesia, aggressiveness and psycho-affective deficit. The use of a low molecular weight heparin with an average molecular weight between 1000 and 10,000 daltons is preferred, mainly between 1500 and 6000 daltons and, in particular, between 4000 and 5000 daltons. Preferably, the low molecular weight heparins are constituted by oligosaccharides that have 2-O-sulfo-4-enopyranosuronic acid in one of their extremities. A particularly advantageous low molecular weight heparin is obtained by depolymerizing an ester of heparin by means of a base such as soda. |
| priorityDate | 1997-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 22.